Nasus Pharma Prices $10M Initial Public Offering Of 1.25M Ordinary Shares At $8.00 Per Share

The Company intends to use the net proceeds from the initial public offering for furthering the development of its intranasal Epinephrine program, including, manufacturing scale-up and additional Phase 2 studies, and the remainder for general and administrative corporate purposes, including working capital, and capital expenditures.